Advanced Cancer Clinical Trial
— CCST2Official title:
Couple Communication Skills Training for Advanced Cancer
The objective of the proposed study is to evaluate the Couple Communication Skills Training (CCST) intervention in 250 patients with advanced cancer and their spouses/intimate partners. Couples will be randomized 1:1 to receive either the CCST or to an attention control condition (Healthy Living Information; HLI). We will evaluate CCST effects on a range of patient and partner relationship and psychological outcomes.
Status | Recruiting |
Enrollment | 460 |
Est. completion date | December 31, 2024 |
Est. primary completion date | December 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Married or in a committed intimate relationship 2. Diagnosis of one the following advanced cancers: Stage IIIB or IV non-small cell lung cancer or extensive stage small cell lung cancer, Stage III pancreatic cancer or Stage IV GI cancer, Stage IV GU cancer, Stage IV breast cancer and GYN cancer Stage III-IV ovarian, IV uterine, IV cervical. 3. Both members of the couple must speak and read English. 4. Patient and/or partner scores >=1.0 on the Holding Back screen. Exclusion Criteria: 1. Patient lacks capacity for interview (documented diagnosis of active psychosis or dementia) or is unable to provide informed consent as assessed by research staff. 2. Patient has a life expectancy < 6 months as estimated by his/her treating oncologist. 3. Patient or partner is physically impaired in such a way that precludes the use of a computer or videoconferencing. 4. Patient or partner is too sick to participate, as judged by the oncologist or research staff. |
Country | Name | City | State |
---|---|---|---|
United States | Duke University Medical Center | Durham | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Duke University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Changes in patient relationship functioning | Change in patient relationship satisfaction measured by the Couples Satisfaction Inventory (higher scores indicate higher satisfaction) | Baseline, end of intervention (up to 8 months), 3 month post intervention follow-up | |
Primary | Changes in partner relationship functioning | Change in partner relationship satisfaction measured by the Couples Satisfaction Inventory (higher scores indicate higher satisfaction) | Baseline, end of intervention (up to 8 months), 3 month post intervention follow-up | |
Primary | Changes in patient relationship functioning | Change in patient intimacy as measured by the Miller Social Intimacy Scale (higher scores indicate higher intimacy) | Baseline, end of intervention (up to 8 months), 3 month post intervention follow-up | |
Primary | Changes in partner relationship functioning | Change in partner intimacy as measured by the Miller Social Intimacy Scale (higher scores indicate higher intimacy) | Baseline, end of intervention (up to 8 months), 3 month post intervention follow-up | |
Secondary | Changes in patient psychological functioning | Change in patient psychological distress measured by the Hospital Anxiety and Depression Scale (higher scores indicate higher distress) | Baseline, end of intervention (up to 8 months), 3 month post intervention follow-up | |
Secondary | Changes in partner psychological functioning | Change in partner psychological distress measured by the Hospital Anxiety and Depression Scale (higher scores indicate higher distress) | Baseline, end of intervention (up to 8 months), 3 month post intervention follow-up | |
Secondary | Changes in patient psychological functioning | Change in patient mood as measured by the Positive and Negative Mood Scale (higher scores on the positive and negative mood subscales indicate higher negative and positive mood, respectively) | Baseline, end of intervention (up to 8 months), 3 month post intervention follow-up | |
Secondary | Changes in partner psychological functioning | Change in partner mood as measured by the Positive and Negative Mood Scale (higher scores on the positive and negative mood subscales indicate higher negative and positive mood, respectively) | Baseline, end of intervention (up to 8 months), 3 month post intervention follow-up | |
Secondary | Changes in patient psychological functioning | Change in patient life completion measured by the Life Completion scale of the QUAL-E (higher scores indicate higher completion) | Baseline, end of intervention (up to 8 months), 3 month post intervention follow-up | |
Secondary | Changes in partner psychological functioning | Change in partner life completion measured by the Life Completion scale of the QUAL-E Family (higher scores indicate higher completion) | Baseline, end of intervention (up to 8 months), 3 month post intervention follow-up | |
Secondary | Changes in patient psychological functioning | Change in patient physical well being as measured by the Physical Well Being subscale of the Functional Assessment of Cancer Therapy scale (higher scores indicate higher physical well being) | Baseline, end of intervention (up to 8 months), 3 month post intervention follow-up | |
Secondary | Changes in patient and partner psychological functioning | Change in symptom distress as measured by the Condensed Memorial Symptom Assessment Scale (higher scores indicate higher symptom distress) | Baseline, end of intervention (up to 8 months), 3 month post intervention follow-up | |
Secondary | Changes in patient psychological functioning | Change in patient advance care planning discussions (presence or absence, via patient self-report) | Baseline, end of intervention (up to 8 months), 3 month post intervention follow-up | |
Secondary | Changes in patient psychological functioning | Change in patient completion of advanced directives (presence or absence, via patient self-report) | Baseline, end of intervention (up to 8 months), 3 month post intervention follow-up | |
Secondary | Changes in patient psychological functioning | Change in patient hospitalizations (number of hospitalizations per patient self-report, validated by medical record review) | Baseline, end of intervention (up to 8 months), 3 month post intervention follow-up | |
Secondary | Changes in patient psychological functioning | Change in patient emergency department visits (number of emergency department visits per patient self-report, validated by medical record review) | Baseline, end of intervention (up to 8 months), 3 month post intervention follow-up |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03181854 -
Randomized Controlled Trial of Integrated Early Palliative Care
|
N/A | |
Completed |
NCT01197170 -
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
|
Phase 1 | |
Recruiting |
NCT05045040 -
Empathetic Communication Facilitation Program for Early Initiation of End-of-life Discussions
|
N/A | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03994601 -
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Completed |
NCT01393990 -
A Study of LY2228820 in Participants With Advanced Cancer
|
Phase 1 | |
Completed |
NCT02857270 -
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT04121676 -
Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer
|
Phase 1 | |
Active, not recruiting |
NCT03177291 -
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
|
Phase 1 | |
Completed |
NCT03980041 -
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
|
Phase 2 | |
Active, not recruiting |
NCT03674567 -
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab
|
Phase 1/Phase 2 | |
Recruiting |
NCT04823377 -
Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer.
|
N/A | |
Completed |
NCT02778126 -
A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer
|
Phase 1 | |
Completed |
NCT02529553 -
A Study of LY3076226 in Participants With Advanced or Metastatic Cancer
|
Phase 1 | |
Completed |
NCT02507544 -
A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer
|
Phase 1 | |
Completed |
NCT02245204 -
Phase I Studies of Chlorogenic Acid for Injection for Tolerance and Pharmacokinetic of Advanced Cancers
|
Phase 1 | |
Terminated |
NCT01929941 -
An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies
|
Phase 1 | |
Completed |
NCT01583777 -
Phase I Mass Balance, PK and Safety Study of 14C-Labeled Belinostat in Patients With Advanced Cancer
|
Phase 1 |